Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light.

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, Dong Z, Bode AM, PetricoinIII EF.

NPJ Precis Oncol. 2017;1. pii: 34. doi: 10.1038/s41698-017-0037-7. Epub 2017 Sep 21.

2.

Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Petricoin EF 3rd, Calvert VS, Einspahr J, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Timothy Bowden G.

Cancer Prev Res (Phila). 2016 Mar;9(3):215-24. doi: 10.1158/1940-6207.CAPR-15-0419. Epub 2016 Jan 22.

3.

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS.

Cancer Prev Res (Phila). 2016 Feb;9(2):128-34. doi: 10.1158/1940-6207.CAPR-15-0232. Epub 2015 Dec 28.

4.

Fyn is a redox sensor involved in solar ultraviolet light-induced signal transduction in skin carcinogenesis.

Kim JE, Roh E, Lee MH, Yu DH, Kim DJ, Lim TG, Jung SK, Peng C, Cho YY, Dickinson S, Alberts D, Bowden GT, Einspahr J, Stratton SP, Curiel-Lewandrowski C, Bode AM, Lee KW, Dong Z.

Oncogene. 2016 Aug 4;35(31):4091-101. doi: 10.1038/onc.2015.471. Epub 2015 Dec 21.

5.

EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN.

Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP.

J Frailty Aging. 2015;4(2):107-10. doi: 10.14283/jfa.2015.48.

6.

Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Bermudez Y, Stratton SP, Curiel-Lewandrowski C, Warneke J, Hu C, Bowden GT, Dickinson SE, Dong Z, Bode AM, Saboda K, Brooks CA, Petricoin EF 3rd, Hurst CA, Alberts DS, Einspahr JG.

Cancer Prev Res (Phila). 2015 Aug;8(8):720-8. doi: 10.1158/1940-6207.CAPR-14-0407. Epub 2015 Jun 1.

7.

Chronic use of NSAIDs and/or statins does not affect PSA or PSA velocity in men at high risk for prostate cancer.

Algotar AM, Behnejad R, Stratton MS, Stratton SP.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2196-8. doi: 10.1158/1055-9965.EPI-14-0605. Epub 2014 Jul 24.

8.

Malondialdehyde-derived epitopes in human skin result from acute exposure to solar UV and occur in nonmelanoma skin cancer tissue.

Williams JD, Bermudez Y, Park SL, Stratton SP, Uchida K, Hurst CA, Wondrak GT.

J Photochem Photobiol B. 2014 Mar 5;132:56-65. doi: 10.1016/j.jphotobiol.2014.01.019. Epub 2014 Feb 12.

9.

Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer.

Algotar AM, Hsu CH, Singh P, Stratton SP.

J Diabetes. 2013 Dec;5(4):465-70. doi: 10.1111/1753-0407.12041. Epub 2013 May 29.

10.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

11.

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.

Baker AF, Adab KN, Raghunand N, Chow H, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T.

Invest New Drugs. 2013 Jun;31(3):631-641. doi: 10.1007/s10637-012-9846-2. Epub 2012 Jun 19.

12.

Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellacani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd.

Cancer Prev Res (Phila). 2012 Mar;5(3):403-13. doi: 10.1158/1940-6207.CAPR-11-0427. Erratum in: Cancer Prev Res (Phila). 2012 Aug;5(8):1072. Pellicani, Giovanni [corrected to Pellacani, Giovanni].

13.

Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.

Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Thompson PA.

Am J Mens Health. 2011 May;5(3):272-8. doi: 10.1177/1557988310390030.

14.

Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Intern Med J. 2012 Apr;42(4):374-80. doi: 10.1111/j.1445-5994.2011.02473.x.

15.

Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer.

Algotar AM, Stratton MS, Xu MJ, Dalkin BL, Nagle RB, Hsu CH, Ahmann FR, Clark LC, Stratton SP.

Nutr Cancer. 2011;63(1):1-5. doi: 10.1080/01635581.2010.516476. No abstract available.

16.

No effect of selenium supplementation on serum glucose levels in men with prostate cancer.

Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR.

Am J Med. 2010 Aug;123(8):765-8. doi: 10.1016/j.amjmed.2010.02.018.

17.

Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.

Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR.

Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. doi: 10.1158/1940-6207.CAPR-09-0143. Epub 2010 Jul 20.

18.

Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP.

Prostate. 2010 Jun 1;70(8):883-8. doi: 10.1002/pros.21122.

19.

A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.

Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, Warneke JA, Curiel-Lewandrowski C, Myrdal PB, Karlage KL, Nickoloff BJ, Brooks C, Saboda K, Yozwiak ML, Krutzsch MF, Hu C, Lluria-Prevatt M, Dong Z, Bowden GT, Bartels PH.

Cancer Prev Res (Phila). 2010 Feb;3(2):160-9. doi: 10.1158/1940-6207.CAPR-09-0183. Epub 2010 Jan 26.

20.

Preformulation, formulation, and in vivo efficacy of topically applied apomine.

Kuehl PJ, Stratton SP, Powell MB, Myrdal PB.

Int J Pharm. 2009 Dec 1;382(1-2):104-10. doi: 10.1016/j.ijpharm.2009.08.016. Epub 2009 Aug 20.

21.

Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT.

J Pharmacol Exp Ther. 2009 Nov;331(2):636-47. doi: 10.1124/jpet.109.156406. Epub 2009 Aug 5.

22.

Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer.

Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, Alberts DS.

Nutr Cancer. 2008;60(3):325-30. doi: 10.1080/01635580701840391.

PMID:
18444166
23.

Cross-validation of murine UV signal transduction pathways in human skin.

Einspahr JG, Bowden GT, Alberts DS, McKenzie N, Saboda K, Warneke J, Salasche S, Ranger-Moore J, Curiel-Lewandrowski C, Nagle RB, Nickoloff BJ, Brooks C, Dong Z, Stratton SP.

Photochem Photobiol. 2008 Mar-Apr;84(2):463-76. doi: 10.1111/j.1751-1097.2007.00287.x. Epub 2008 Jan 29.

PMID:
18248498
24.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
25.

A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.

Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T.

Clin Cancer Res. 2007 Apr 1;13(7):2109-14.

26.

Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.

Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP.

Invest New Drugs. 2007 Apr;25(2):107-14. Epub 2006 Oct 6.

PMID:
17024575
27.

Promising agents for chemoprevention of skin cancer.

Stratton SP, Stratton MS, Alberts DS.

Curr Oncol. 2006 Oct;13(5):185-6. No abstract available.

28.

Development of an HPLC method for the analysis of Apomine in a topical cream formulation.

Kuehl PJ, Angersbach BS, Stratton SP, Myrdal PB.

J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80. Epub 2005 Sep 21.

PMID:
16181759
29.

An HPLC method for quantitation of perillyl alcohol in a topical pharmaceutical cream formulation.

Gupta A, Stratton SP, Myrdal PB.

J Pharm Biomed Anal. 2005 Mar 9;37(3):447-52. Epub 2005 Jan 13.

PMID:
15740902
30.

Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse.

Mustacich D, Wagner A, Williams R, Bair W, Barbercheck L, Stratton SP, Bhattacharyya AK, Powis G.

Carcinogenesis. 2004 Oct;25(10):1983-9. Epub 2004 May 27.

PMID:
15166090
31.

Chemoprevention of human skin cancer.

Einspahr JG, Stratton SP, Bowden GT, Alberts DS.

Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85. Review.

PMID:
11880204
32.

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.

Clin Cancer Res. 2002 Feb;8(2):314-46.

33.

Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression.

Gupta A, Butts B, Kwei KA, Dvorakova K, Stratton SP, Briehl MM, Bowden GT.

Cancer Lett. 2001 Nov 28;173(2):115-25.

PMID:
11597785
34.

Prevention of non-melanoma skin cancer.

Stratton SP.

Curr Oncol Rep. 2001 Jul;3(4):295-300. Review.

PMID:
11389812
35.

Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice.

Stratton SP, Bangert JL, Alberts DS, Dorr RT.

Cancer Lett. 2000 Sep 29;158(1):47-52.

PMID:
10940508
36.

The state-of-the-art in chemoprevention of skin cancer.

Stratton SP, Dorr RT, Alberts DS.

Eur J Cancer. 2000 Jun;36(10):1292-7. Review.

PMID:
10882869
38.
39.

Isolation and identification of singlet oxygen oxidation products of beta-carotene.

Stratton SP, Schaefer WH, Liebler DC.

Chem Res Toxicol. 1993 Jul-Aug;6(4):542-7.

PMID:
8374054

Supplemental Content

Loading ...
Support Center